8-year event-free-survival ( EFS , 64 8 % vs. 81 1 % , p = 0.0026 ) and cumulative incidence of relapse ( CIR , 29 8 % vs. 14 1 % , p = 0.008 ) of the iAMP21 cases were significantly worse compared with non-iAMP21 patients .